DNA Methylation Marker Panel for Liver Cancer Recurrence Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to accurately predict the prognosis of liver cancer patients, particularly the likelihood of recurrence, which affects the choice of appropriate treatment and survival outcomes.
Innovation Solution
A composition comprising DNA methylation markers (cg21325760, cg10544510, cg06702718, and cg15997204) is used to predict liver cancer recurrence by analyzing methylation levels in liver tissues, employing techniques like Illumina® Infinium HumanMethylation 850K bead array and machine learning algorithms to classify patients into risk groups.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA methylation markers are used to predict liver cancer recurrence, then prediction accuracy is improved, but measurement precision requirements increase
Solution Approach 1:
The patent divides the complex task of liver cancer recurrence prediction into multiple independent methylation marker measurements. Instead of relying on a single comprehensive marker, the invention uses a panel of specific CpG sites (cg21325760, cg10544510, cg06702718, cg15997204) that can be measured separately and combined, thereby improving overall prediction accuracy while maintaining manageable measurement precision requirements for each individual marker.
Solution Approach 2:
The invention transforms the prediction problem by changing the measurement parameters from general tumor markers to specific DNA methylation levels at defined CpG sites. This parameter change enables more accurate and specific prediction of recurrence, as methylation patterns provide distinct molecular signatures that correlate with patient outcomes.
2Reliability
If multiple DNA methylation markers are analyzed, then prediction accuracy is improved, but device complexity increases
Solution Approach 1:
The patent employs a universal methylation analysis platform (such as Illumina Infinium HumanMethylation 850K bead array) that can simultaneously measure multiple CpG sites across the genome. This multi-functional device allows the analysis of all four specified methylation markers in a single assay, improving prediction accuracy without proportionally increasing device complexity, as the same platform handles all measurements.
3Reliability
If DNA methylation analysis is performed on liver tissues, then recurrence prediction capability is improved, but ease of operation decreases
Solution Approach 1:
The invention performs DNA extraction and methylation analysis on liver tissue samples obtained during initial surgery or biopsy. By conducting the methylation profiling early in the treatment course, the prediction of recurrence is established before treatment decisions are finalized, allowing clinicians to plan appropriate follow-up strategies in advance without requiring additional invasive procedures later.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DNA methylation markers provide accurate prediction of liver cancer recurrence, enabling personalized treatment strategies and reducing unnecessary treatments, with high accuracy and sensitivity.
Implementation Method 1
the difference in methylation levels of genomic DNA according to a liver cancer prognosis
Data Source
AI summary
The present invention relates to a DNA methylation marker for predicting the recurrence of liver cancer by using the difference in the DNA methylation levels according to a liver cancer prognosis, and when the marker is used, the recurrence of liver cancer can be easily predicted, and a more personalized treatment for patients at high risk of liver cancer recurrence can be provided and clinical information for avoiding unnecessary over-treatment can be provided.